title: An unusual DNA binding compound, S23906, induces mitotic catastrophe in cultured human cells.
abstract: The biochemical pathways that lead cells to mitotic catastrophe are not well understood. To identify these pathways, we have taken an approach of treating cells with a novel genotoxic compound and characterizing whether cells enter mitotic catastrophe or not. S23906 is a novel acronycine derivative that forms adducts with the N2 residue of guanine in the minor groove of the DNA helix and destabilizes base pairing to cause helix opening. We observed, in HeLa and HT-29 cells, that S23906 induced gamma-H2AX and activated checkpoint kinase 1, as did bleomycin, camptothecin, and cisplatin, when tested under equi-toxic conditions. S23906 also induced cyclin E1 protein, although this activity was not required for cytotoxicity because knock down of cyclin E1 by RNA interference did not affect the number of dead cells after treatment. Cyclin B1 levels first decreased and then increased after treatment with S23906. Cyclin B1 was associated with Cdk1 kinase activity, which correlated with an increase in the number of mitotic cells. By 32 h after treatment, at least 20% of the cells entered mitotic catastrophe as determined by microscopy. Suppression of the DNA checkpoint response by co-treatment with caffeine increased the number of cells in mitosis. These results suggest that mitotic catastrophe is one of the cellular responses to S23906 and that mitotic catastrophe may be a common cellular response to many different types of DNA damage.
authors.affiliation: Institut de Recherches Servier, Cancer Research Division, Croissy-sur Seine, France.
authors.forename: Nathalie
authors.initials: N
authors.lastname: Cahuzac
authors.forename: Aurélie
authors.initials: A
authors.lastname: Studény
authors.forename: Kris
authors.initials: K
authors.lastname: Marshall
authors.forename: Isabella
authors.initials: I
authors.lastname: Versteege
authors.forename: Kate
authors.initials: K
authors.lastname: Wetenhall
authors.forename: Bruno
authors.initials: B
authors.lastname: Pfeiffer
authors.forename: Stéphane
authors.initials: S
authors.lastname: Léonce
authors.forename: John A
authors.initials: JA
authors.lastname: Hickman
authors.forename: Alain
authors.initials: A
authors.lastname: Pierré
authors.forename: Roy M
authors.initials: RM
authors.lastname: Golsteyn
mesh_terms: D000175:Acronine / Q000031:analogs & derivatives* / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects; D015152:Blotting, Northern; D016203:CDC2 Protein Kinase / Q000378:metabolism; D002110:Caffeine / Q000494:pharmacology; D056744:Cyclin B1 / Q000378:metabolism; D019927:Cyclin E / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism; D004247:DNA / Q000378:metabolism*; D005455:Fluorescent Antibody Technique; D019073:HT29 Cells; D006367:HeLa Cells; D006801:Humans; D008938:Mitosis / Q000187:drug effects*; D015513:Oncogene Proteins / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism; D034741:RNA, Small Interfering / Q000494:pharmacology
chemical_list: D000970:Antineoplastic Agents; C475820:CCNE1 protein, human; D056744:Cyclin B1; D019927:Cyclin E; D015513:Oncogene Proteins; D034741:RNA, Small Interfering; C436732:S 23906-1; D002110:Caffeine; D004247:DNA; D016203:CDC2 Protein Kinase; D000175:Acronine